{
    "2021-05-17": [
        [
            {
                "time": "",
                "original_text": "博雅生物回复问询函：公司血液制品业务毛利率高于可比上市公司平均水平，具有合理性 问询",
                "features": {
                    "keywords": [
                        "博雅生物",
                        "血液制品",
                        "毛利率",
                        "高于",
                        "可比上市公司",
                        "合理性"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}